Encorafenib (Braftovi)

CADTH recommends that Braftovi should be reimbursed by public drug plans for the treatment of metastatic colorectal cancer (mCRC) if certain conditions are met. Braftovi should only be reimbursed when given in combination with cetuximab, prescribed by clinicians with experience in treating colorectal cancer, and the cost of Braftovi is reduced. Braftovi should only be covered for patients who have BRAF V600E–mutated mCRC, have received at least 1 previous systemic treatment for mCRC, have good performance status, and have adequate organ function. Braftovi should not be reimbursed for patients who have had previous treatment with epidermal growth factor receptor (EGFR) inhibitors or BRAF inhibitors.